Skip to main content

Advertisement

SpringerLink
Log in

Postmenopausal osteoporosis

  • Published:
Current Osteoporosis Reports Aims and scope Submit manuscript

Abstract

The postmenopausal state is the most common underlying cause for osteoporosis and most of our understanding of the condition relates to this group. Recent evidence has suggested that hormone therapy may no longer have the pre-eminent place it once held but the same studies have also confirmed its antifracture efficacy. However, an increasing variety of alternative therapies are available for the postmenopausal woman. Furthermore, recent understanding of the mechanisms of bone loss, after estrogen withdrawal suggest that newer even better targeted therapies might be developed in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

References and Recommended Reading

  1. Albright F: Hormones and human osteogenesis. Recent Prog Horm Res 1947, 1:293–353.

    CAS  PubMed  Google Scholar 

  2. Rossouw JE, Anderson GL, Prentice RL, et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002, 288:321–333. A huge, well conducted, double blind randomized controlled trial of HT. This study examines the beneficial and adverse effects of this treatment and concludes that for most women risk of long term treatment will outweigh the benefits.

    Article  PubMed  CAS  Google Scholar 

  3. Cauley JA, Robbins J, Chen Z, et al.: Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 2003, 290:1729–1738.

    Article  PubMed  CAS  Google Scholar 

  4. Beral V: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003, 362:419–427.

    Article  PubMed  CAS  Google Scholar 

  5. Anderson GL, Limacher M, Assaf AR, et al.: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004, 291:1701–1712.

    Article  PubMed  CAS  Google Scholar 

  6. Raudaskoski T, Tapanainen J, Tomas E, et al.: Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. BJOG 2002, 109:136–144.

    PubMed  CAS  Google Scholar 

  7. Ettinger B, Black DM, Mitlak BH, et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282:637–645.

    Article  PubMed  CAS  Google Scholar 

  8. Cummings SR, Eckert S, Krueger KA, et al.: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999, 281:2189–2197.

    Article  PubMed  CAS  Google Scholar 

  9. Reginster J, Minne HW, Sorensen OH, et al.: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000, 11:83–91.

    Article  PubMed  CAS  Google Scholar 

  10. Sorensen OH, Crawford GM, Mulder H, et al.: Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003, 32:120–126.

    Article  PubMed  CAS  Google Scholar 

  11. Bone HG, Hosking D, Devogelaer JP, et al.: Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350:1189–1199.

    Article  PubMed  CAS  Google Scholar 

  12. Liberman UA, Weiss SR, Broll J, et al.: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995, 333:437–1443.

    Article  Google Scholar 

  13. Cooper C, Emkey RD, McDonald RH, et al.: Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2003, 88:4609–4615.

    Article  PubMed  CAS  Google Scholar 

  14. McCloskey E, Selby P, Davies M, et al.: Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebocontrolled 3-year study. J Bone Miner Res 2004, 19:728–736.

    Article  PubMed  CAS  Google Scholar 

  15. Stakkestad JA, Benevolenskaya LI, Stepan JJ, et al.: Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis 2003, 62:969–975.

    Article  PubMed  CAS  Google Scholar 

  16. Reid IR, Brown JP, Burckhardt P, et al.: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002, 346:653–661.

    Article  PubMed  CAS  Google Scholar 

  17. Neer RM, Arnaud CD, Zanchetta JR, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434–1441. This is a pivotal clinical trial demonstrating the use of PTH on fractures.

    Article  PubMed  CAS  Google Scholar 

  18. Marcus R, Wang O, Satterwhite J, Mitlak B: The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003, 18:18–23.

    Article  PubMed  CAS  Google Scholar 

  19. Cummings SR, Palermo L, Browner W, et al.: Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA 2000, 283:1318–1321. A secondary analysis of results in two trials of osteoporosis therapies that has been widely interpreted as indicating that monitoring of bone mineral density is of little clinical utility.

    Article  PubMed  CAS  Google Scholar 

  20. Black DM, Greenspan SL, Ensrud KE, et al.: The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349:1207–1215.

    Article  PubMed  CAS  Google Scholar 

  21. Finkelstein JS, Hayes A, Hunzelman JL, et al.: The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003, 349:1216–1226.

    Article  PubMed  CAS  Google Scholar 

  22. Hodsman AB, Hanley DA, Ettinger MP, et al.: Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003, 88:5212–5220.

    Article  PubMed  CAS  Google Scholar 

  23. Brown EM: Is the calcium receptor a molecular target for the actions of strontium on bone? Osteoporos Int 2003, 14(Suppl 3):S25-S34.

    PubMed  CAS  Google Scholar 

  24. Buehler J, Chappuis P, Saffar JL, et al.: Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Bone 2001, 29:176–179.

    Article  PubMed  CAS  Google Scholar 

  25. Marie PJ, Hott M, Modrowski D, et al.: An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogendeficient rats. J Bone Miner Res 1993, 8:607–615.

    Article  PubMed  CAS  Google Scholar 

  26. Meunier PJ, Slosman DO, Delmas PD, et al.: Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis—a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002, 87:2060–2066. A pivotal clinical trial demonstrating the use of strontium ranelate in established postmenopausal vertebral osteoporosis.

    Article  PubMed  CAS  Google Scholar 

  27. Meunier PJ, Roux C, Seeman E, et al.: The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004, 350:459–468.

    Article  PubMed  CAS  Google Scholar 

  28. Albright F, Smith PH, Richardson AM: Postmenopausal osteoporosis: its clinical features. JAMA 1941, 116:2465–2474.

    Google Scholar 

  29. Erikson EF, Colvard DS, Berg NJ, et al.: Evidence of estrogen receptors in normal human osteoblast like cells. Science 1988, 241:84–86.

    Article  Google Scholar 

  30. Shevde NK, Bendixen AC, Dienger KM, Pike JW: Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci U S A 2000, 97:7829–7834.

    Article  PubMed  CAS  Google Scholar 

  31. Eghbali-Fatourechi G, Khosla S, Sanyal A, et al.: Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003, 111:1221–1230.

    Article  PubMed  CAS  Google Scholar 

  32. Bekker PJ, Holloway D, Nakanishi A, et al.: The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001, 16:348–360.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Department of Medicine, Manchester Royal Infirmary, Oxford Road, M13 9WL, Manchester, UK

    Peter Selby MA, MD, FRCP

Authors
  1. Peter Selby MA, MD, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Selby, P. Postmenopausal osteoporosis. Curr Osteoporos Rep 2, 101–106 (2004). https://doi.org/10.1007/s11914-004-0018-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11914-004-0018-y

Keywords

Search

Navigation